Indeed, JAK-targeting TKI have reached the clinics recently, several of which also target JAK2 with low micromolar concentration to exert pro-apoptotic effects in CML cells in vitro (reviewed in [66]). Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.